amsacrine has been researched along with Leucocythaemia in 100 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Excerpt | Relevance | Reference |
---|---|---|
" The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 9.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
"The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 9.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
"Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 9.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
"This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 7.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
"Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 7.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
"The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 7.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
"The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 7.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
"The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 7.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
"Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 7.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
"Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 7.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
"Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 7.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
"The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 7.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
"In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 7.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
"We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 7.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
"Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 7.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
"Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 7.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
" The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 5.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
"The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 5.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
"This clinical trial (DT7995) was designed to evaluate amsacrine (AMSA) plus cytosine arabinoside (ara-C), vincristine, and prednisone (OAP) therapy in previously untreated patients with adult acute leukemia and to investigate a new strategy for assignment of patients to treatment using estimated probabilities of complete remission (PPR) based on six prognostic factors." | 5.06 | A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. ( Estey, EH; Freireich, EJ; Gehan, EA; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Walters, RS, 1987) |
"Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 5.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
"Amsacrine is an antileukemia drug being widely used in North America, Europe, Australia, and New Zealand." | 5.06 | Amsacrine-associated cardiotoxicity: an analysis of 82 cases. ( Grillo-López, AJ; Hess, F; Marsoni, S; Posada, JG; Ross, BJ; Weiss, RB, 1986) |
"This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 3.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
" The single-arm trial evaluated amsacrine plus cytosine arabinoside, vincristine, and prednisone (a combination abbreviated as OAP) for adult acute leukemia, when standard treatment was adriamycin plus OAP." | 3.75 | Treatment-subgroup interaction: an example from a published, phase II clinical trial. ( Behrendt, CE; Gehan, EA, 2009) |
"Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 3.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
"The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 3.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
"The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 3.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
"The coumermycin antibiotic novobiocin, which interacts with the nuclear enzyme topoisomerase II, produced supra-additive toxicity to WEHI-3B D+ leukemia cells at clinically achievable concentrations, when combined with teniposide (VM-26) or etoposide (VP-16)." | 3.68 | Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). ( Lorico, A; Rappa, G; Sartorelli, AC, 1992) |
"The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 3.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
"Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 3.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
"The ability of a noncytotoxic dose of ara-C to modulate the amount of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA)- or etoposide-induced topoisomerase II-mediated DNA cleavage and cytotoxicity was examined in m-AMSA-sensitive and -resistant HL-60 human leukemia cells." | 3.67 | Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le ( Andersson, BS; Bakic, M; Beran, M; Chan, D; Estey, E; Ricketts, L; Silberman, L; Zwelling, LA, 1987) |
"Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 3.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
"The ECG effect of amsacrine (m-AMSA) was evaluated in 12 consecutive patients with leukemia." | 3.67 | Acute electrocardiographic changes induced by amsacrine. ( Hasin, Y; Shinar, E, 1984) |
"The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 3.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
"In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 3.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
"Thirty-five adults with acute nonlymphocytic leukemia who were in complete remission after initial induction therapy received a single course of high-dose cytarabine and amsacrine as consolidation therapy." | 3.67 | Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. ( Begg, CB; Bennett, JM; Burkart, PT; Cassileth, PA; Knospe, WH; Mazza, JJ; Oken, MM; Scharfman, W; Silber, R; Spiers, A, 1987) |
"Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 3.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
"Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 3.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
"We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 3.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
"Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults." | 3.67 | [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults]. ( Ogawa, M, 1986) |
"Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 3.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
"m-AMSA is a new drug in the National Cancer Institute Drug Development Program." | 2.65 | m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. ( Charles, LM; Macdonald, JS; Weiss, RB, 1980) |
"Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL." | 2.65 | Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. ( Civin, CI; Frankel, LS; Krischer, J; Land, VJ; Mahoney, DH; Ragab, AH, 1984) |
"The sinusitis was successfully treated with AmBisome, and surgical debridement." | 1.33 | Zygomycosis in the immunocompromised patient: a case report. ( Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M, 2006) |
" push in a dosage of 150 mg/m2 for 5 days." | 1.27 | 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. ( Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983) |
"A pharmacokinetic study was performed in 13 adult patients with acute nonlymphoblastic leukemia to compare two formulations of 4'-(9-acridinylamino)-methanesulphone-m-ansidide (AMSA): the original formulation, AMSA-NCL, and a water-soluble lyophilized formulation, AMSA-lactate (Bristol Myers, Syracuse, N." | 1.27 | Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ( Farmen, RH; Franks, CR; Liliemark, JO; Paul, CY; Peterson, CO; Uytdenhoef, M, 1987) |
"Hyperbilirubinemia was seen in 25% of the patients treated." | 1.26 | Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. ( Arlin, ZA; Clarkson, BD; Gee, TS; Howard, J; Kempin, SJ; Sklaroff, RB; Young, CW, 1980) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 71 (71.00) | 18.7374 |
1990's | 22 (22.00) | 18.2507 |
2000's | 5 (5.00) | 29.6817 |
2010's | 1 (1.00) | 24.3611 |
2020's | 1 (1.00) | 2.80 |
Authors | Studies |
---|---|
Spicer, JA | 1 |
Gamage, SA | 1 |
Atwell, GJ | 1 |
Finlay, GJ | 4 |
Baguley, BC | 7 |
Denny, WA | 1 |
Kolb, HJ | 1 |
Schmid, C | 1 |
Liu, WH | 1 |
Chen, YJ | 1 |
Chien, JH | 1 |
Chang, LS | 1 |
Behrendt, CE | 1 |
Gehan, EA | 2 |
Tauro, S | 1 |
Shankaranarayana, P | 1 |
Nitu-Whalley, IC | 1 |
Duncan, N | 1 |
Begum, G | 1 |
Craig, JI | 1 |
Marcus, RE | 1 |
Craddock, CF | 1 |
Mahendra, P | 1 |
Boutonnat, J | 1 |
Faussat, AM | 1 |
Marie, JP | 1 |
Bignon, J | 1 |
Wdzieczak-Bakala, J | 1 |
Barbier, M | 1 |
Thierry, J | 1 |
Ronot, X | 1 |
Colle, PE | 1 |
Georgala, A | 1 |
Vekemans, M | 1 |
Husson, M | 1 |
Meuleman, N | 1 |
Beguin, H | 1 |
Nolard, N | 1 |
Aoun, M | 1 |
Carella, AM | 1 |
Santini, G | 1 |
Marmont, AM | 1 |
Miller, LP | 1 |
Miller, DR | 2 |
Tan, CT | 2 |
Kahn, SB | 2 |
Sklaroff, R | 1 |
Lebedda, J | 1 |
Conroy, JF | 1 |
Bulova, S | 1 |
Brodsky, I | 1 |
Gahrton, G | 1 |
Hines, JD | 3 |
Oken, MM | 5 |
Mazza, JJ | 4 |
Keller, AM | 1 |
Streeter, RR | 1 |
Glick, JH | 3 |
Arlin, ZA | 9 |
Carter, SK | 1 |
Naparstek, E | 1 |
Shinar, E | 2 |
Polliack, A | 1 |
Cassileth, PA | 2 |
Lyman, GH | 1 |
Bennett, JM | 4 |
Omura, GA | 1 |
Winton, EF | 1 |
Vogler, WR | 1 |
Zuckerman, KS | 1 |
Grillo-Lopez, AJ | 2 |
Estey, EH | 2 |
Keating, MJ | 5 |
Smith, TL | 2 |
McCredie, KB | 7 |
Legha, SS | 4 |
Walters, RS | 2 |
Bodey, GP | 4 |
Freireich, EJ | 4 |
Krischer, J | 1 |
Land, VJ | 1 |
Civin, CI | 1 |
Ragab, AH | 1 |
Mahoney, DH | 1 |
Frankel, LS | 1 |
Case, DC | 1 |
Hasin, Y | 1 |
Mittelman, A | 4 |
Zander, AR | 1 |
Vellekoop, L | 1 |
Dicke, KA | 1 |
Spitzer, G | 1 |
Verma, D | 1 |
Check, WA | 1 |
Goldsmith, MA | 1 |
Bhardwaj, S | 1 |
Ohnuma, T | 1 |
Greenspan, EM | 1 |
Holland, JF | 1 |
Flomenberg, N | 1 |
Gee, TS | 2 |
Kempin, SJ | 2 |
Dellaquila, C | 1 |
Mertelsmann, R | 1 |
Straus, DJ | 1 |
Young, CW | 2 |
Clarkson, BD | 2 |
Hancock, C | 1 |
Steinherz, PG | 1 |
Steinherz, LJ | 1 |
Sorell, M | 1 |
Chan, KW | 1 |
Mondora, A | 1 |
Mahal, PS | 1 |
Valdivieso, M | 1 |
Luna, M | 1 |
Benjamin, RS | 1 |
Ahmann, FR | 1 |
Meyskens, FL | 1 |
Moon, TE | 1 |
Durie, BG | 1 |
Salmon, SE | 1 |
Horikoshi, N | 1 |
Ogawa, M | 2 |
Inagaki, J | 1 |
Ezaki, K | 1 |
Inoue, K | 1 |
Okabe, K | 1 |
Nagata, T | 1 |
Aiba, K | 1 |
Domyo, M | 1 |
Sklaroff, RB | 1 |
Howard, J | 1 |
Fanucchi, MP | 1 |
Macdonald, JS | 2 |
Marsoni, S | 2 |
Bruno, S | 1 |
Poster, D | 1 |
Weiss, RB | 2 |
Charles, LM | 1 |
Lawrence, HJ | 1 |
Ries, CA | 1 |
Reynolds, RD | 1 |
Lewis, JP | 1 |
Koretz, MM | 1 |
Torti, FM | 1 |
Boege, F | 2 |
Biersack, H | 2 |
Meyer, P | 2 |
Ellis, AL | 1 |
Nowak, B | 2 |
Plunkett, W | 3 |
Zwelling, LA | 7 |
Mayes, J | 3 |
Hinds, M | 3 |
Soares, L | 1 |
Altschuler, E | 3 |
Kim, P | 1 |
Lyytikäinen, O | 1 |
Elonen, E | 1 |
Lautenschlager, I | 1 |
Jokipii, A | 1 |
Tiittanen, L | 1 |
Ruutu, P | 1 |
Riou, JF | 1 |
Davey, RA | 1 |
Su, GM | 1 |
Hargrave, RM | 1 |
Harvie, RM | 1 |
Davey, MW | 1 |
Ma, XJ | 1 |
Xiang, YM | 1 |
Hong, J | 1 |
Laurençot, CM | 1 |
Scheffer, GL | 1 |
Scheper, RJ | 1 |
Shoemaker, RH | 1 |
Laroche-Clary, A | 1 |
Larrue, A | 1 |
Robert, J | 1 |
Mitchell, MJ | 1 |
Satitpunwaycha, P | 1 |
Gieseler, F | 1 |
Granzen, B | 1 |
Graves, DE | 1 |
Danks, MK | 2 |
Beck, WT | 2 |
Rappa, G | 1 |
Lorico, A | 1 |
Sartorelli, AC | 1 |
Ehninger, G | 1 |
Proksch, B | 1 |
Wanner, T | 1 |
Schuler, U | 1 |
Busch, FW | 1 |
Schmidt, H | 1 |
Schleyer, E | 1 |
Jaschonek, K | 1 |
Hiddemann, W | 2 |
Chan, D | 3 |
Richel, DJ | 1 |
Colly, LP | 1 |
Kluin-Nelemans, JC | 1 |
Willemze, R | 2 |
Feldman, EJ | 1 |
Ahmed, T | 3 |
Puccio, C | 1 |
Chun, HG | 1 |
Cook, P | 1 |
Baskind, P | 2 |
Marboe, C | 1 |
Mehta, R | 3 |
Snow, K | 1 |
Judd, W | 1 |
Fernandes, DJ | 1 |
Marit, G | 1 |
Cony, P | 1 |
Duclos, F | 1 |
Puntous, M | 1 |
Broustet, A | 1 |
Reiffers, J | 1 |
Cunningham, M | 1 |
Hanauske, AR | 2 |
Hanauske, U | 1 |
Von Hoff, DD | 2 |
Spiers, A | 2 |
Knospe, WH | 2 |
Soojian, M | 1 |
Brons, PP | 1 |
Wessels, JM | 1 |
Linssen, PC | 1 |
Haanen, C | 2 |
Speth, PA | 1 |
Jehn, U | 3 |
Estey, E | 2 |
Bakic, M | 2 |
Silberman, L | 2 |
Andersson, BS | 3 |
Beran, M | 3 |
Ricketts, L | 1 |
Maschmeyer, G | 1 |
Kreutzmann, H | 1 |
Wendt, F | 1 |
Adelstein, DJ | 2 |
Keller, A | 2 |
O'Connell, MJ | 2 |
Petti, MC | 1 |
Avvisati, G | 1 |
Tafuri, A | 1 |
Meloni, G | 1 |
Amadori, S | 1 |
Mandelli, F | 1 |
Liang, R | 1 |
Chan, TK | 1 |
Todd, D | 1 |
Dhaliwal, HS | 1 |
Shannon, MS | 1 |
Barnett, MJ | 1 |
Prentice, HG | 1 |
Bragman, K | 1 |
Malpas, JS | 1 |
Lister, TA | 1 |
Posada, JG | 1 |
Hess, F | 1 |
Ross, BJ | 1 |
Feldman, E | 2 |
Weinstein, P | 1 |
Rieber, E | 2 |
Sullivan, P | 2 |
Van Mouwerik, TJ | 1 |
Caines, PM | 1 |
Ballentine, R | 1 |
Kantarjian, HM | 1 |
Arlin, Z | 1 |
Pucillo, A | 1 |
Tallman, MS | 1 |
Appelbaum, FR | 1 |
Amos, D | 1 |
Goldberg, RS | 1 |
Livingston, RB | 1 |
Mortimer, J | 1 |
Weiden, PL | 1 |
Thomas, ED | 1 |
Stuckey, SE | 1 |
Mavligit, GM | 1 |
Schiffer, CA | 1 |
Davis, RB | 1 |
Mayer, RJ | 1 |
Peterson, BA | 1 |
Lee, EJ | 1 |
Dekker, AW | 1 |
Punt, K | 1 |
Verdonck, LF | 1 |
Paul, CY | 1 |
Liliemark, JO | 1 |
Farmen, RH | 1 |
Franks, CR | 1 |
Uytdenhoef, M | 1 |
Peterson, CO | 1 |
Lindpaintner, K | 1 |
Lindpaintner, LS | 1 |
Wentworth, M | 1 |
Burns, CP | 1 |
Abrams, RA | 1 |
Hanson, G | 1 |
Hansen, RM | 1 |
Anderson, T | 1 |
Odaimi, M | 1 |
Wilson, WR | 1 |
Keating, M | 1 |
Begg, CB | 1 |
Silber, R | 1 |
Burkart, PT | 1 |
Scharfman, W | 1 |
Letendre, L | 1 |
Hinemann, V | 1 |
Hoagland, HC | 1 |
Kovach, JS | 1 |
Gaddipati, J | 1 |
Friedland, M | 1 |
Zittoun, R | 2 |
Bury, J | 1 |
Stryckmans, P | 1 |
Lowenberg, B | 1 |
Peetermans, M | 1 |
Rozendaal, KY | 1 |
Kerkhofs, M | 1 |
Louie, AC | 1 |
Issell, BF | 1 |
Edelstein, M | 1 |
Valeriote, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
13 reviews available for amsacrine and Leucocythaemia
Article | Year |
---|---|
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Foreca | 2020 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone | 1983 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Nonhematologic toxicities of selected chemotherapeutic agents used in the treatment of adult leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; | 1990 |
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Topics: Aminoacridines; Amsacrine; Animals; Anthracenes; Antineoplastic Agents; Blood Physiological Phenomen | 1985 |
Topoisomerase II as a target of antileukemia drugs: a review of controversial areas.
Topics: Amsacrine; Antineoplastic Agents; DNA; DNA Topoisomerases, Type II; Humans; Leukemia | 1989 |
New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA.
Topics: Acute Disease; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 1989 |
New strategies in the management of acute leukemias.
Topics: Acute Disease; Amsacrine; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Cytosine arabinoside in experimental combination therapy.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyl | 1985 |
m-AMSA: a review of clinical data.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Drug Evalu | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
14 trials available for amsacrine and Leucocythaemia
Article | Year |
---|---|
[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Child, Preschool; Female; Humans; Leukemia; Male; Middle | 1997 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Drug Administrat | 1984 |
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow Transplantation; | 1982 |
m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Topics: Acute Disease; Aminoacridines; Amsacrine; Breast Neoplasms; Clinical Trials as Topic; Dose-Response | 1980 |
AMSA--a promising new agent in refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Cli | 1982 |
Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
Topics: Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies | 1986 |
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Amsacrine evaluation.
Topics: Adult; Amsacrine; Child; Clinical Trials as Topic; Humans; Kinetics; Leukemia; Neoplasms | 1987 |
A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arabinofurano | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
77 other studies available for amsacrine and Leucocythaemia
Article | Year |
---|---|
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leuk | 1997 |
Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells.
Topics: Amsacrine; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Leuke | 2014 |
Treatment-subgroup interaction: an example from a published, phase II clinical trial.
Topics: Acute Disease; Adult; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; He | 2003 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Br | 2005 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agen | 2006 |
Amsacrine and 5-azacytidine in acute non lymphatic leukaemia (ANLL).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Azacitidine; Humans; Leukemia | 1982 |
Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; C | 1983 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Ther | 1983 |
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1984 |
Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Bone Marrow; Cytarabine; Drug Evaluation; Drug Therapy | 1984 |
High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Sc | 1984 |
Phase II study of amsacrine gluconate in refractory leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke | 1983 |
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leuke | 1984 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
Acute electrocardiographic changes induced by amsacrine.
Topics: Acute Disease; Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic C | 1984 |
AMSA-induced seizures in patients with hypokalemia.
Topics: Aminoacridines; Amsacrine; Female; Humans; Hypokalemia; Leukemia; Middle Aged; Seizures | 1983 |
Laboratory-designed drug used against leukemia.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia | 1980 |
Phase I study of m-AMSA in patients with solid tumors and leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Chemical and Drug Induced Liver I | 1980 |
Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Chemical a | 1981 |
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool | 1982 |
AMSA toxicity in patients with abnormal liver function.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; Hum | 1981 |
In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cells, Cultured; Drug Evaluation; Female; Genital | 1982 |
[Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1982 |
Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Drug Administration Schedule; Drug Evaluation; Humans; | 1980 |
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H | 1982 |
Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; | 1982 |
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor | 1982 |
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA Topoisomerases, Type II; DNA-Binding Prote | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisom | 1994 |
Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
Topics: Adenosine Triphosphate; Amsacrine; Anions; Catalysis; DNA; DNA Damage; DNA Topoisomerases, Type II; | 1993 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus | 1996 |
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Topics: Acridines; Amsacrine; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topois | 1996 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 1997 |
[Venous protection of acute leukemia treatment with amsacrine].
Topics: Acute Disease; Amsacrine; Antineoplastic Agents; Fluid Therapy; Humans; Leukemia; Phlebitis | 1996 |
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Topics: Amsacrine; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Nucleus; Cisplatin; Coloni | 1997 |
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; bcl-X Protein; Chromatography, High Pressure Liquid; Do | 2000 |
Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Topics: Amsacrine; Benzenesulfonamides; Carbamates; Computer Simulation; DNA Topoisomerases, Type I; DNA Top | 1992 |
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniq | 1992 |
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Division; DN | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA T | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Inter | 1992 |
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Alkaloids; Amsacrine; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Respon | 1991 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemot | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M | 1991 |
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
Topics: Amsacrine; Drug Resistance; Humans; Leukemia; Structure-Activity Relationship; Topoisomerase II Inhi | 1990 |
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Nucleus; Crithidia; DNA; DNA Topoisomerases, Type II | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1990 |
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; | 1987 |
Determination of amsacrine in human nucleated hematopoietic cells.
Topics: Amsacrine; Chromatography, High Pressure Liquid; Dextrans; Hematopoietic System; Humans; Leukemia; L | 1987 |
Topoisomerase II as a target of antileukemic drugs.
Topics: Amsacrine; Animals; DNA Topoisomerases, Type II; Drug Resistance; Humans; Leukemia; Leukemia, Experi | 1987 |
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le
Topics: Amsacrine; Cell Division; Cell Nucleus; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistanc | 1987 |
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; E | 1987 |
Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1987 |
Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1988 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas | 1986 |
Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.
Topics: Acute Disease; Aged; Amsacrine; Arrhythmia, Sinus; Atrial Fibrillation; Female; Humans; Leukemia; Mi | 1987 |
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1987 |
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil.
Topics: Acute Disease; Adult; Aged; Amsacrine; Cells, Cultured; Doxorubicin; Drug Resistance; Drug Synergism | 1987 |
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Aziridi | 1987 |
The use of amsacrine plus intermediate-dose cytosine arabinoside in relapsed and refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukem | 1987 |
Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Female; Humans; Lactates; Lactic Acid; Leukemia; | 1987 |
Acute myocardial necrosis during administration of amsacrine.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Electrocardiography; Female; Humans; Leukemia; Mid | 1986 |
Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; | 1986 |
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Topics: Aminoacridines; Amsacrine; Cell Line; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Etopo | 1986 |
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cell Count; Cell Line; Cell Survival; Colonic Neop | 1986 |
Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Rela | 1986 |
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leuke | 1985 |
Amsacrine: a new drug for hematological malignancies.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Humans; Intercalating Agents; Leukemia; Lymphoma | 1985 |
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combine | 1985 |
High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 1985 |
Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |
Amsacrine with high-dose cytarabine in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1985 |
[Experiences with HD-Ara C treatment in leukemia patients].
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |